Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety Tolerability Pharmacokinetics Pharmacodynamics and Initial Efficacy of ASK8007 in Comparison With Placebo in Patients With Active Rheumatoid Arthritis - a Randomized Double Blind Placebo-Controlled Combined Single Dose Escalation and Multiple Dose Study

Next Previous
X
Search
Trial Profile

Safety Tolerability Pharmacokinetics Pharmacodynamics and Initial Efficacy of ASK8007 in Comparison With Placebo in Patients With Active Rheumatoid Arthritis - a Randomized Double Blind Placebo-Controlled Combined Single Dose Escalation and Multiple Dose Study

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASK 8007 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions

    • Most Recent Events

    • 14 Sep 2011 Results published in the Annals of the Rheumatic Diseases.
    • 14 Apr 2009 Planned number of patients changed from 48 to 54, additional trial location identified as reported by ClinicalTrials.gov
    • 14 Apr 2009 Planned end date changed from 1 Mar 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top